Ultragenyx Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Update
Retrieved on:
Thursday, February 11, 2021
For the fourth quarter of 2020, Ultragenyx reported $91.5 million in total revenue.
Key Points:
- For the fourth quarter of 2020, Ultragenyx reported $91.5 million in total revenue.
- Mepsevii (vestronidase alfa) product sales for the fourth quarter of 2020 were $3.7 million.
- Total operating expenses for the fourth quarter of 2020 were $187.6 million, including non-cash stock-based compensation of $22.8 million.
- ET to discuss the fourth quarter and year 2020 financial results and provide a corporate update.